Research programme: antibody-drug conjugate therapeutics - Synaffix

Drug Profile

Research programme: antibody-drug conjugate therapeutics - Synaffix

Latest Information Update: 25 Feb 2017

Price : $50

At a glance

  • Originator Synaffix
  • Developer Synaffix; Unknown
  • Class Antibodies; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Feb 2017 Preclinical trials in Cancer in Netherlands, before February 2017 (Synaffix website)
  • 08 Dec 2016 Synaffix has patent protection for GlycoConnect™ antibody-drug conjugate technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top